![Catharine Porter](https://profiles-cardiff.imgix.net/attachments/3629?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Catharine Porter
Cyswllt Ymchwil - Ystadegau
- PorterC3@caerdydd.ac.uk
- Neuadd Meirionnydd, Ystafell 514, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4YS
- Ar gael fel goruchwyliwr ôl-raddedig
Trosolwyg
Rwy'n Gydymaith Ymchwil mewn Ystadegau yn y Ganolfan Ymchwil Treialon ym Mhrifysgol Caerdydd lle rwyf wedi gweithio ers mis Medi 2014. I ddechrau, ymunais ag Uned Treialon Canser Cymru a unodd yn ddiweddarach ag unedau treialon eraill ym Mhrifysgol Caerdydd i ddod yn Ganolfan Treialon Ymchwil. O'r herwydd, fy mhrif feysydd o ddiddordeb yw treialon tiwmor a haematoleg solet. Rwyf wedi datblygu cyfoeth o brofiad dros y blynyddoedd wrth ddatblygu a chynnal treialon clinigol canser, o geisiadau cyllido cychwynnol a dylunio treialon clinigol, trwy ddatblygu cyn y treial gan gynnwys Ffurflenni Adroddiad Achos, metadata a datblygu cronfa ddata, mae'r cam recriwtio yn cynnwys monitro data yn ganolog ac adrodd i Bwyllgorau monitro Data Annibynnol, glanhau data cyn dadansoddiad terfynol, cyflwyno crynodebau i gynadleddau a chyhoeddiadau terfynol mewn cyfnodolion o fri rhyngwladol. Rwy'n uwch ystadegydd ar dreialon ac yn goruchwylio ystadegwyr iau yn y prosiectau hyn.
Rwyf wedi gweithio am flynyddoedd lawer fel Rheolwr Data mewn Haematoleg Glinigol ac mae gen i brofiad helaeth o dreialon Clinigol Haematoleg o ochr yr ysbyty yn ogystal â'r ochr Treialon Dat.
Mae gennyf BSc (Anrh) mewn Gwyddorau Biolegol gyda Biocemeg, PhD mewn Biocemeg (Prifysgol Birmingham) a Meistr mewn Iechyd y Cyhoedd (Prifysgol Caerdydd). Rwyf wedi cynnal Cymrodoriaethau Ymchwil Ôl-ddoethurol mewn Bioleg Foleciwlaidd a Geneteg.
Cyhoeddiad
2022
- Fennell, D. A. et al. 2022. Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine 52, article number: 101595. (10.1016/j.eclinm.2022.101595)
- Fennell, D. A. et al. 2022. Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. eClinicalMedicine 48, article number: 101432. (10.1016/j.eclinm.2022.101432)
2021
- Byrne, A., Adamson, D., Porter, C. and Hurt, C. 2021. Stent insertion for incurable oesophageal carcinoma: what is the optimal treatment? - authors' reply. The Lancet Gastroenterology & Hepatology 6(7), article number: 525. (10.1016/S2468-1253(21)00174-6)
- Adamson, D. et al. 2021. Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT. Health Technology Assessment 25(31) (10.3310/hta25310)
- Adamson, D. et al. 2021. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial. Lancet Gastroenterology and Hepatology 6(4), pp. 292-303. (10.1016/S2468-1253(21)00004-2)
2020
- Byrne, A. T. et al. 2020. Radiotherapy after esophageal cancer stenting (ROCS): A pragmatic randomized controlled trial evaluating the role of palliative radiotherapy in maintaining swallow.. Journal of Clinical Oncology 38(15_sup), article number: 4569. (10.1200/JCO.2020.38.15_suppl.4569)
2019
- Hurt, C. et al. 2019. Feasibility and economic assessment of chromocolonoscopy for detection of proximal serrated neoplasia within a population-based colorectal cancer screening programme (CONSCOP): an open-label, randomised controlled non-inferiority trial. Lancet Gastroenterology and Hepatology 4(5), pp. 364-375. (10.1016/S2468-1253(19)30035-4)
2018
- Prout, H. C. et al. 2018. Patient understanding and acceptability of an early lung cancer diagnosis trial: a qualitative study. Trials 19, article number: 419. (10.1186/s13063-018-2803-4)
2017
- Neal, R. D. et al. 2017. Immediate chest X-ray for patients at risk of lung cancer presenting in primary care: randomised controlled feasibility trial. British Journal of Cancer 116(3), pp. 293-302. (10.1038/bjc.2016.414)
Erthyglau
- Fennell, D. A. et al. 2022. Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine 52, article number: 101595. (10.1016/j.eclinm.2022.101595)
- Fennell, D. A. et al. 2022. Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. eClinicalMedicine 48, article number: 101432. (10.1016/j.eclinm.2022.101432)
- Byrne, A., Adamson, D., Porter, C. and Hurt, C. 2021. Stent insertion for incurable oesophageal carcinoma: what is the optimal treatment? - authors' reply. The Lancet Gastroenterology & Hepatology 6(7), article number: 525. (10.1016/S2468-1253(21)00174-6)
- Adamson, D. et al. 2021. Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT. Health Technology Assessment 25(31) (10.3310/hta25310)
- Adamson, D. et al. 2021. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial. Lancet Gastroenterology and Hepatology 6(4), pp. 292-303. (10.1016/S2468-1253(21)00004-2)
- Byrne, A. T. et al. 2020. Radiotherapy after esophageal cancer stenting (ROCS): A pragmatic randomized controlled trial evaluating the role of palliative radiotherapy in maintaining swallow.. Journal of Clinical Oncology 38(15_sup), article number: 4569. (10.1200/JCO.2020.38.15_suppl.4569)
- Hurt, C. et al. 2019. Feasibility and economic assessment of chromocolonoscopy for detection of proximal serrated neoplasia within a population-based colorectal cancer screening programme (CONSCOP): an open-label, randomised controlled non-inferiority trial. Lancet Gastroenterology and Hepatology 4(5), pp. 364-375. (10.1016/S2468-1253(19)30035-4)
- Prout, H. C. et al. 2018. Patient understanding and acceptability of an early lung cancer diagnosis trial: a qualitative study. Trials 19, article number: 419. (10.1186/s13063-018-2803-4)
- Neal, R. D. et al. 2017. Immediate chest X-ray for patients at risk of lung cancer presenting in primary care: randomised controlled feasibility trial. British Journal of Cancer 116(3), pp. 293-302. (10.1038/bjc.2016.414)
Ymchwil
Fy niddordebau ymchwil yw treialon clinigol mewn oncoleg, tiwmorau solet a haematoleg.
Fel ystadegydd treial, rwy'n cymryd rhan mewn treialon clinigol, o ddylunio treialon hyd at ddadansoddiad terfynol a chyhoeddi, gan gynhyrchu dadansoddiad interim ar gyfer pwyllgorau monitro data a monitro data yn ganolog.
Ar hyn o bryd rwy'n gweithio ar dreialon Cam 1-3 mewn lewcemia lymffoblastig acíwt, canser y croen, canser rhefrol, mesothelioma plewrol, canser yr ysgyfaint, canser yr oesoffageal, atal COVID mewn cleifion imiwnoataliedig a chanser endometrial.
Rwyf hefyd yn aelod Annibynnol ar Bwyllgorau Llywio Monitro Data a Threial.
Bywgraffiad
Addysg a Chymwysterau
- 2014: Meistr mewn Iechyd y Cyhoedd, Prifysgol Caerdydd, y DU
- 1989: PhD (Biocemeg), Prifysgol Birmingham, UK
- 1985: BSc (Anrh) Gwyddorau Biolegol, Prifysgol East Anglia
Trosolwg gyrfa
- Ionawr 2019 i gyflwyno: Cydymaith Ymchwil (Ystadegau), Canolfan Ymchwil Treialon Prifysgol Caerdydd
- Hydref 2017-Ionawr 2019: Cyswllt Ymchwil Dros Dro (Ystadegau), Canolfan Ymchwil Treialon Prifysgol Caerdydd
- 2014-Hydref 2017: Cynorthwy-ydd Ymchwil (Ystadegau), Uned Treialon Canser Cymru, Prifysgol Caerdydd
- 2001-2005: Cydlynydd Data, Haematoleg Glinigol ac Uned Trawsblannu Mêr Esgyrn, Ysbyty Athrofaol Birmingham
- 1998-2001: Rheolwr Data, Haematoleg Glinigol ac Uned Trawsblannu Mêr Esgyrn, Ysbyty Cadarnleoedd Birmingham
Safleoedd academaidd blaenorol
- 1989-1993: Cymrawd Ymchwil Ôl-ddoethurol, Ysgol Gwyddorau Biolegol, Prifysgol Birmingham
Meysydd goruchwyliaeth
Ystadegau meddygol (yn enwedig oncoleg)
Themâu ymchwil
Arbenigeddau
- Haematoleg
- Oncoleg a charsinogenesis
- Treialon clinigol
- Treialon Canser